NeuroMetrix, Inc.

NasdaqCM:NURO Stock Report

Market Cap: US$8.7m

NeuroMetrix Valuation

Is NURO undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NURO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NURO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NURO's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NURO?

Key metric: As NURO is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for NURO. This is calculated by dividing NURO's market cap by their current revenue.
What is NURO's PS Ratio?
PS Ratio2.3x
SalesUS$3.77m
Market CapUS$8.68m

Price to Sales Ratio vs Peers

How does NURO's PS Ratio compare to its peers?

The above table shows the PS ratio for NURO vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average0.5x
TRIB Trinity Biotech
0.2x11.8%US$11.5m
SCND Scientific Industries
0.7xn/aUS$7.9m
CUTR Cutera
0.04x2.4%US$6.4m
BMRA Biomerica
1xn/aUS$5.3m
NURO NeuroMetrix
2.3xn/aUS$8.7m

Price-To-Sales vs Peers: NURO is expensive based on its Price-To-Sales Ratio (2.3x) compared to the peer average (0.5x).

Price to Sales Ratio vs Industry

How does NURO's PS Ratio compare vs other companies in the US Medical Equipment Industry?

50 CompaniesPrice / SalesEstimated GrowthMarket Cap
INGN Inogen
0.7x4.2%US$223.42m
ARAY Accuray
0.4x5.5%US$194.09m
NVRO Nevro
0.4x2.5%US$169.37m
KEQU Kewaunee Scientific
0.6xn/aUS$125.50m
NURO 2.3xIndustry Avg. 3.3xNo. of Companies50PS02.85.68.411.214+
50 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: NURO is good value based on its Price-To-Sales Ratio (2.3x) compared to the US Medical Equipment industry average (3.3x).

Price to Sales Ratio vs Fair Ratio

What is NURO's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NURO PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate NURO's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Lantheus Holdings

US$6.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$90.52

7D

18.8%

1Y

27.5%

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

ELV

US$402.55

7D

0.5%

1Y

-15.7%

electroCore

US$72.3m

A commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.

ECOR

US$11.21

7D

16.2%

1Y

99.5%